Filing Flows

Filing Flows › 8-K events › Syndax Pharmaceuticals

Syndax Pharmaceuticals: results of operations

Form 8-K filed Nov 2, 2026 · items 2.02, 5.02

CFO changesSyndax Reports Third Quarter 2026 Financial Results and Provides Business Update

What the filing says

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update • Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase –

ScaleThe filing names $83.3M: about 25% of Syndax Pharmaceuticals' annual revenue ($333.2M, four times the latest quarter).

Read the filing on SEC EDGAR →

What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Item 5.02: −0.1% next session across 39,174. Every item ranked →

What this kind of filing means

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Syndax Pharmaceuticals at a glance

Latest quarterQ3 2026
Revenue$83.3M
Revenue Y/Y+82%
Operating margin-50.3%
IndustryPharmaceutical Preparations

Syndax Pharmaceuticals, Q3 2026: revenue $83.3M (+82% year over year), operating margin -50.3%. The chart follows the revenue to costs, profit and cash.

Syndax Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent cfo changes

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.